[f18]-asem (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18f]fluorodibenzo[b,d]thiophene 5,5-dioxide)
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2019 (NCT04055467)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04055467 | Phase 1 | Sep 30, 2019 | Johns Hopkins University, National Institute on Drug Abuse (NIDA) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1